• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neutralization Potential of Covishield Vaccinated Individuals Sera Against B.1.617.1.

作者信息

Yadav Pragya D, Sapkal Gajanan N, Abraham Priya, Deshpande Gururaj, Nyayanit Dimpal A, Patil Deepak Y, Gupta Nivedita, Sahay Rima R, Shete Anita M, Kumar Sanjay, Panda Samiran, Bhargava Balram

机构信息

Indian Council of Medical Research-National Institute of Virology, PuneIndia.

Indian Council of Medical Research, V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi, India.

出版信息

Clin Infect Dis. 2022 Feb 11;74(3):558-559. doi: 10.1093/cid/ciab483.

DOI:10.1093/cid/ciab483
PMID:34036309
Abstract
摘要

相似文献

1
Neutralization Potential of Covishield Vaccinated Individuals Sera Against B.1.617.1.接种Covishield疫苗个体血清对B.1.617.1的中和潜力
Clin Infect Dis. 2022 Feb 11;74(3):558-559. doi: 10.1093/cid/ciab483.
2
CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant.科兴和国药疫苗接种和伽马感染诱导针对 SARS-CoV-2 德尔塔变异株的中和抗体。
Viruses. 2022 Feb 1;14(2):305. doi: 10.3390/v14020305.
3
Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.腺病毒载体 ChAdOx1 疫苗和 BNT162b2 疫苗引起的抗体反应比较。
J Korean Med Sci. 2021 Nov 29;36(46):e311. doi: 10.3346/jkms.2021.36.e311.
4
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
5
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.异源 ChAdOx1-BNT162b2 疫苗接种的免疫原性和疗效。
Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21.
6
High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.在感染 HIV-1 亚型 B 的个体的血清中，针对多种不相关的人类免疫缺陷病毒 1 型（HIV-1）亚型 B 变体的中和活性的高流行率：针对亚型特异性而非株特异性的中和活性的证据。
J Gen Virol. 2010 Jan;91(Pt 1):250-8. doi: 10.1099/vir.0.015693-0. Epub 2009 Sep 30.
7
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.奥密克戎对抗体中和作用的逃逸显著。
Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23.
8
Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination.接种者的先天免疫反应决定了接种 ChAdOx1nCoV-19 后的早期中和抗体产生。
Front Immunol. 2022 Jan 25;13:807454. doi: 10.3389/fimmu.2022.807454. eCollection 2022.
9
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.使用弗林蛋白酶切割的人乳头瘤病毒假病毒对接种基于人乳头瘤病毒L1或L2免疫原的患者的中和血清抗体进行测量。
PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.
10
Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.异源加强 COVID-19 疫苗接种方案的免疫原性和安全性：ChAdOx1 疫苗 Covishield 加 BBV152 疫苗 Covaxin。
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab166.

引用本文的文献

1
Clinical characterization, molecular and genomic sequencing analysis of SARS-Cov-2 during second wave at Raigarh, Chhattisgarh, India.印度恰蒂斯加尔邦赖加德第二波新冠疫情期间新冠病毒的临床特征、分子及基因组测序分析
Bioinformation. 2024 Sep 30;20(9):1059-1064. doi: 10.6026/9732063002001059. eCollection 2024.
2
Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India.印度成年人对 AZD1222/Covishield 和 BV152/Covaxin COVID-19 疫苗的体液和细胞免疫反应。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2410579. doi: 10.1080/21645515.2024.2410579. Epub 2024 Oct 21.
3
Utility of COVID-19 Seropositive Plasma as Convalescent Plasma: An Immune and Neutralization Antibody Seroprevalence Analysis in Blood Donors for Future Potential Pandemic Readiness.
新冠病毒血清阳性血浆作为恢复期血浆的效用：对献血者进行免疫和中和抗体血清流行率分析以应对未来潜在大流行。
Cureus. 2024 Mar 28;16(3):e57149. doi: 10.7759/cureus.57149. eCollection 2024 Mar.
4
SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants.SARS-CoV-2 之旅：从阿尔法变异株到奥密克戎及其亚变异株。
Infection. 2024 Jun;52(3):767-786. doi: 10.1007/s15010-024-02223-y. Epub 2024 Mar 30.
5
A SARS-CoV-2: Companion Animal Transmission and Variants Classification.严重急性呼吸综合征冠状病毒2：伴侣动物传播与变异分类
Pathogens. 2023 May 29;12(6):775. doi: 10.3390/pathogens12060775.
6
Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform.在印度，对野生型（B.1）病毒、Kappa（B.1.617.1）和 Delta（B.1.617.2）变体以及 COVISHIELD 疫苗免疫的自然感染中，针对 10 种 SARS-CoV-2 变体的可变中和抗体反应：MSD 平台的实用性。
Front Immunol. 2023 Jun 5;14:1181991. doi: 10.3389/fimmu.2023.1181991. eCollection 2023.
7
Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19.基于先进等离子体纳米颗粒的技术用于当前新型冠状病毒肺炎的预防、检测和治疗
Plasmonics. 2023;18(1):311-347. doi: 10.1007/s11468-022-01754-0. Epub 2022 Dec 23.
8
Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses.基于 SARS-CoV-2 结构蛋白的 B 细胞和 T 细胞表位的生物信息学分析及其与新兴变异株和其他人类冠状病毒的潜在交叉反应性。
Arch Med Res. 2022 Nov;53(7):694-710. doi: 10.1016/j.arcmed.2022.10.007. Epub 2022 Nov 3.
9
Novel coronavirus mutations: Vaccine development and challenges.新型冠状病毒突变：疫苗开发与挑战。
Microb Pathog. 2022 Dec;173(Pt A):105828. doi: 10.1016/j.micpath.2022.105828. Epub 2022 Oct 13.
10
Protective effect conferred by prior infection and vaccination on COVID-19 in a healthcare worker cohort in South India.在印度南部的一个医护人员队列中，既往感染和接种疫苗对 COVID-19 的保护作用。
PLoS One. 2022 May 20;17(5):e0268797. doi: 10.1371/journal.pone.0268797. eCollection 2022.